PriceTargets.com logo

Boundless Bio - BOLD Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $3.50
  • Forecasted Upside: 215.32%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 3 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.11 As of 12/4/2025 04:53 PM ET
▼ -1.19 (-51.74%)
Get New Boundless Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BOLD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BOLD

Analyst Price Target is $3.50
▲ +215.32% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Boundless Bio in the last 3 months. The average price target is $3.50, with a high forecast of $4.00 and a low forecast of $3.00. The average price target represents a 215.32% upside from the last price of $1.11.

This chart shows the closing price for BOLD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 polled investment analysts is to hold stock in Boundless Bio. This rating has held steady since April 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/11/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/5/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/28/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/14/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
8/11/2025HC WainwrightLower TargetBuy ➝ Buy$5.00 ➝ $4.00
6/2/2025HC WainwrightInitiated CoverageBuy$5.00
5/28/2025Leerink PartnersDowngradeOutperform ➝ Market Perform$15.00 ➝ $3.00
5/27/2025Leerink PartnrsDowngradeStrong-Buy ➝ Hold
12/13/2024GuggenheimDowngradeBuy ➝ Neutral
4/22/2024Piper SandlerInitiated CoverageOverweight$20.00
4/22/2024GuggenheimInitiated CoverageBuy$24.00
4/22/2024Leerink PartnersInitiated CoverageOutperform$25.00
(Data available from 12/5/2020 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/7/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/5/2025
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Boundless Bio logo
Audentes Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. It is also developing vectorized antisense treatments for the treatment of duchenne muscular dystrophy and myotonic dystrophy type 1. The company has a collaborative development agreement with Genethon to research, develop, manufacture, and commercialize products for the treatment of XLMTM; and a license and collaboration agreement with the University of Pennsylvania to research, develop, sell, and import licensed products for the treatment of crigler-najjar. Audentes Therapeutics, Inc. was founded in 2012 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $1.11
Low: $2.36
High: $2.58

50 Day Range

MA: $59.97
Low: $59.97
High: $59.97

52 Week Range

Now: $1.11
Low: $1.00
High: $4.72

Volume

96,520 shs

Average Volume

159,237 shs

Market Capitalization

$24.85 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Boundless Bio?

The following Wall Street sell-side analysts have issued reports on Boundless Bio in the last twelve months: Guggenheim, HC Wainwright, Leerink Partners, Leerink Partnrs, and Weiss Ratings.
View the latest analyst ratings for BOLD.

What is the current price target for Boundless Bio?

0 Wall Street analysts have set twelve-month price targets for Boundless Bio in the last year. Their average twelve-month price target is $3.50, suggesting a possible upside of 215.3%. HC Wainwright has the highest price target set, predicting BOLD will reach $4.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $3.00 for Boundless Bio in the next year.
View the latest price targets for BOLD.

What is the current consensus analyst rating for Boundless Bio?

Boundless Bio currently has 1 sell rating, 3 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BOLD, but not buy more shares or sell existing shares.
View the latest ratings for BOLD.

What other companies compete with Boundless Bio?

Other companies that are similar to Boundless Bio include Anebulo Pharmaceuticals, Adagene, TuHURA Biosciences, Pliant Therapeutics and Adverum Biotechnologies. Learn More about companies similar to Boundless Bio.

How do I contact Boundless Bio's investor relations team?

Boundless Bio's physical mailing address is 600 CALIFORNIA ST. 17TH FLOOR, SAN FRANCISCO CA, 94108. The biotechnology company's listed phone number is 415-818-1001 and its investor relations email address is [email protected]. The official website for Boundless Bio is www.audentestx.com. Learn More about contacing Boundless Bio investor relations.